Postoperative Nausea Vomiting Treatment

Post-operative Nausea and Vomiting (PONV) Market (Treatment Type - Serotonin Antagonists, Steroids, Dopamine Antagonists, NK-1 Receptor Antagonists, Non-pharmacological Treatment; Distribution Channel - Hospital Pharmacies, Online Pharmacies, Retail Pharmacies & Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

  • Rep Id : TMRGL2969
  • Published On : Jul 2018
  • No. of Pages : 166
  • Category : Pharmaceutical

Chapter 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2 Assumptions and Research Methodology

Chapter 3 Executive Summary: Global Post-operative Nausea and Vomiting (PONV) Market

Chapter 4 Market Overview
4.1. Introduction
4.2. Key Industry Developments

Chapter 5 Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Trends
5.5. Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, 2016–2026
5.6. Global Post-operative Nausea and Vomiting (PONV) Market Outlook

Chapter 6 Market Outlook
6.1. Absolute Surgical Procedure Volume, by Region
6.2. Incidence of Post-operative Nausea and Vomiting, by Region, (2017 - Estimated)
6.3. Post-operative Nausea and Vomiting (PONV) Market: Pipeline Analysis

Chapter 7 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Treatment Type
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
       7.3.1. Serotonin Antagonists
       7.3.2. Steroids
       7.3.3. Dopamine Antagonists
       7.3.4. NK-1 receptor Antagonists
       7.3.5. Non-Pharmacologic Treatment
7.4. Market Attractiveness Analysis, by Treatment Type

Chapter 8 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings
8.2. Global PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
       8.2.1. Hospital Pharmacies
       8.2.2. Online Pharmacies
       8.2.3. Retail Pharmacies and Drug Stores
8.3. Global PONV Market Attractiveness Analysis, by Distribution Channel
8.4. Key Trends

Chapter 9 Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Global PONV Market Value (US$ Mn) Forecast, by Region, 2018–2026
       9.3.1. North America
       9.3.2. Europe
       9.3.3. Asia Pacific
       9.3.4. Latin America
       9.3.5. Middle East & Africa
9.4. Global PONV Market Attractiveness Analysis, by Region

Chapter 10 North America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
10.1. Key Findings
10.2. North America PONV Market Size (US$ Mn) Forecast, by Country, 2018–2026
       10.2.1. U.S.
       10.2.2. Canada
10.3. North America PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
       10.3.1. Serotonin Antagonists
       10.3.2. Steroids
       10.3.3. Dopamine Antagonists
       10.3.4. NK-1 receptor Antagonists
       10.3.5. Non-pharmacologic Treatment
10.4. North America PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
       10.4.1. Hospital Pharmacies
       10.4.2. Online Pharmacies
       10.4.3. Retail Pharmacies and Drug Stores
10.5. North America PONV Market Attractiveness Analysis
       10.5.1. By Country
       10.5.2. By Treatment Type
       10.5.3. By Distribution Channel

Chapter 11 Europe Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
11.1. Key Findings
11.2. Europe PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
       11.2.1. Germany
       11.2.2. U.K.
       11.2.3. France
       11.2.4. Italy
       11.2.5. Spain
       11.2.6. Russia
       11.2.7. Rest of Europe
11.3. Europe PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
       11.3.1. Serotonin Antagonists
       11.3.2. Steroids
       11.3.3. Dopamine Antagonists
       11.3.4. NK-1 receptor Antagonists
       11.3.5. Non-Pharmacologic Treatment
11.4. Europe PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
       11.4.1. Hospital Pharmacies
       11.4.2. Online Pharmacies
       11.4.3. Retail Pharmacies and Drug Stores
11.5. Europe PONV Market Attractiveness Analysis
       11.5.1. By Country
       11.5.2. By Treatment Type
       11.5.3. By Distribution Channel

Chapter 12 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
       12.3.1. China
       12.3.2. India
       12.3.3. Japan
       12.3.4. Australia & New Zealand
       12.3.5. Rest of Asia Pacific
12.4. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
       12.4.1. Serotonin Antagonists
       12.4.2. Steroids
       12.4.3. Dopamine Antagonists
       12.4.4. NK-1 receptor Antagonists
       12.4.5. Non-Pharmacologic Treatment
12.5. Asia Pacific PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
       12.5.1. Hospital Pharmacies
       12.5.2. Online Pharmacies
       12.5.3. Retail Pharmacies and Drug Stores
12.6. Asia Pacific PONV Market Attractiveness Analysis
       12.6.1. By Country
       12.6.2. By Treatment Type
       12.6.3. By Distribution Channel

Chapter 13 Latin America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Latin America PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
       13.3.1. Brazil
       13.3.2. Mexico
       13.3.3. Rest of Latin America
13.4. Latin America PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
       13.4.1. Serotonin Antagonists
       13.4.2. Steroids
       13.4.3. Dopamine Antagonists
       13.4.4. NK-1 receptor Antagonists
       13.4.5. Non-Pharmacologic Treatment
13.5. Latin America PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
       13.5.1. Hospital Pharmacies
       13.5.2. Online Pharmacies
       13.5.3. Retail Pharmacies and Drug Stores
13.6. Latin America PONV Market Attractiveness Analysis
       13.6.1. By Country
       13.6.2. By Treatment Type
       13.6.3. By Distribution Channel

Chapter 14 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
       14.3.1. GCC Countries
       14.3.2. South Africa
       14.3.3. Israel
       14.3.4. Rest of Middle East & Africa
14.4. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Treatment Type, 2018–2026
       14.4.1. Serotonin Antagonists
       14.4.2. Steroids
       14.4.3. Dopamine Antagonists
       14.4.4. NK-1 receptor Antagonists
       14.4.5. Non-Pharmacologic Treatment
14.5. Middle East & Africa PONV Market Size (US$ Mn) Forecast, by Distribution Channel, 2018–2026
       14.5.1. Hospital Pharmacies
       14.5.2. Online Pharmacies
       14.5.3. Retail Pharmacies and Drug Stores
14.6. Middle East & Africa PONV Market Attractiveness Analysis
       14.6.1. By Country
       14.6.2. By Treatment Type
       14.6.3. By Distribution Channel

Chapter 15 Competition Landscape
15.1. Global Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Key Players and Their Competitive Positioning
15.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
       15.3.1. Acacia Pharma
                 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.1.2. Product Portfolio
                 15.3.1.3. SWOT Analysis
                 15.3.1.4. Strategic Overview
       15.3.2. F. Hoffmann La Roche Ltd.
                 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.2.2. Product Portfolio
                 15.3.2.3. SWOT Analysis
                 15.3.2.4. Strategic Overview
       15.3.3. ANI Pharmaceuticals
                 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.3.2. Product Portfolio
                 15.3.3.3. SWOT Analysis
                 15.3.3.4. Financial Overview
                 15.3.3.5. Strategic Overview
       15.3.4. Sanofi
                 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.4.2. Product Portfolio
                 15.3.4.3. SWOT Analysis
                 15.3.4.4. Financial Overview
                 15.3.4.5. Strategic Overview
       15.3.5. GlaxoSmithKline Corporation
                 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.5.2. Product Portfolio
                 15.3.5.3. SWOT Analysis
                 15.3.5.4. Financial Overview
                 15.3.5.5. Strategic Overview
       15.3.6. Eisai Co., Inc.
                 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.6.2. Product Portfolio
                 15.3.6.3. SWOT Analysis
                 15.3.6.4. Financial Overview
                 15.3.6.5. Strategic Overview
       15.3.7. Merck KGaA
                 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.7.2. Product Portfolio
                 15.3.7.3. SWOT Analysis
                 15.3.7.4. Financial Overview
                 15.3.7.5. Strategic Overview
       15.3.8. Novartis AG
                 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.8.2. Product Portfolio
                 15.3.8.3. SWOT Analysis
                 15.3.8.4. Financial Overview
                 15.3.8.5. Strategic Overview
       15.3.9. Helsinn Holding Co.
                 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.9.2. Product Portfolio
                 15.3.9.3. SWOT Analysis
                 15.3.9.4. Financial Overview
                 15.3.9.5. Strategic Overview
       15.3.10. Camurus AB
                 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                 15.3.10.2. Product Portfolio
                 15.3.10.3. SWOT Analysis
                 15.3.10.4. Financial Overview
                 15.3.10.5. Strategic Overview

List of Tables:

Table 01 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 02 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 03 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 04 North America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country, 2016–2026
Table 05 North America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 06 North America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 07 Europe Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 08 Europe Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 09 Europe Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 10 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 11 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 12 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13 Latin America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14 Latin America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 15 Latin America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 16 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 17 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 18 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Figures:

Figure 01 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn), by Distribution Channel, 2017
Figure 02 Global Post-operative Nausea and Vomiting (PONV) Market Size, by Treatment Type (US$ Mn), 2017
Figure 03 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn), by Region, 2017 and 2026
Figure 04 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, 2016–2026
Figure 05 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast, 2016–2026
Figure 06 Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2017 and 2026
Figure 07 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Serotonin Antagonists, 2016–2026
Figure 08 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Steroids, 2016–2026
Figure 09 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Dopamine Antagonists, 2016–2026
Figure 10 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by NK1 Receptor Antagonists, 2016–2026
Figure 11 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2016–2026
Figure 12 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Non-pharmacologic Treatment, 2016–2026
Figure 13 Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type
Figure 14 Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
Figure 15 Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 16 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Hospital Pharmacies, 2016–2026
Figure 17 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Online Pharmacies, 2016–2026
Figure 18 Global Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) and Y-o-Y Growth, by Retail Pharmacies and Drug Stores, 2016–2026
Figure 19 Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Region, 2016 and 2025
Figure 20 Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Region
Figure 21 North America Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country, 2017 and 2026
Figure 22 North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country, 2018–2026
Figure 23 North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
Figure 24 North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
Figure 25 North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
Figure 26 North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 27 Europe Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 28 Europe Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 29 Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 30 Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
Figure 31 Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
Figure 32 Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
Figure 33 Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 34 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
Figure 35 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 36 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 37 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
Figure 38 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
Figure 39 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
Figure 40 Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 41 Latin America Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 42 Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 43 Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 44 Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
Figure 45 Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
Figure 46 Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
Figure 47 Latin America Postoperative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 48 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
Figure 49 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 50 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 51 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment
Figure 52 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Treatment, 2018–2026
Figure 53 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel
Figure 54 Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness, by Distribution Channel, 2018–2026
Figure 55 Acacia Pharma Research & Development Cost, 2015 – 2017 (US$ Mn)
Figure 56 F. Hoffmann-La Roche Ltd Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 57 F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Region, 2017
Figure 58 F. Hoffmann-La Roche Ltd Breakdown of Net Sales, by Business Segment, 2017
Figure 59 F. Hoffmann-La Roche Ltd Research & Development Cost, 2015 - 2017 (US$ Mn)
Figure 60 Novartis AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 61 Novartis AG Breakdown of Net Sales, by Region, 2017
Figure 62 Novartis AG Breakdown of Net Sales, by Business Segment, 2017
Figure 63 Novartis AG Breakdown of Net Sales, by Innovative Medicines Business Units, 2017
Figure 64 ANI Pharmaceuticals Inc. Research & Development Cost, 2015 - 2017 (US$ Mn)
Figure 65 ANI Pharmaceuticals Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 66 Camurus AB Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 67 Camurus AB Breakdown of Net Sales, by Region, 2017
Figure 68 Camurus AB Breakdown of Net Sales, by Business Segment, 2017
Figure 69 Camurus AB Research & Development Cost (US$ Mn), 2016–2017
Figure 70 Sanofi Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 71 Sanofi Breakdown of Net Sales, by Region, 2017
Figure 72 Sanofi Breakdown of Net Sales, by Business Segment, 2017
Figure 73 Sanofi Breakdown of Net Sales, by Pharmaceuticals, 2017 
Figure 74 Eisai Inc. Breakdown of Net Sales, by Region, 2017
Figure 75 Eisai Inc. R&D Intensity Company Level (US$ Mn), 2016–2017
Figure 76 Eisai Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 77 Helsinn Healthcare S.A. Breakdown of Net Sales, by Region, 2016 (%)
Figure 78 Helsinn Healthcare S.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014-2016
Figure 79 Merck Group, Revenue (US$ Mn), 2015-2017
Figure 80 EMEND Revenue (US$ Mn), 2015-2017
Figure 81 EMEND Revenue, by Region (%), 2017
Figure 82 GSK’s Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2017
Figure 83 R&D Expenditure (US$ Mn), GSK Group, 2015-2017
Figure 84 Breakdown of GSK’s Vaccines Segment Net Sales, by Region, 2017
Figure 85 Breakdown of GSK’s Net Sales, by Business Segment, 2017

.